NO327455B1 - Ecteinascidin forbindelser, anvendelser derav samt farmasoytiske preparat - Google Patents

Ecteinascidin forbindelser, anvendelser derav samt farmasoytiske preparat Download PDF

Info

Publication number: NO327455B1
Authority: NO; Norway
Prior art keywords: compounds; ddd; ecteinascidin compounds; ecteinascidin; pharmaceutical preparations
Prior art date: 1997-04-15

Application number

NO19995016A

Other languages

English (en)

Norwegian (no)

Other versions

NO995016D0 (no

NO995016L (no

Inventor

Kenneth Lloyd Rinehart

Tong Zhou

Original Assignee

Univ Illinois

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-15

Filing date

1999-10-14

Publication date

2009-07-06

1999-10-14 Application filed by Univ Illinois filed Critical Univ Illinois

1999-10-14 Publication of NO995016D0 publication Critical patent/NO995016D0/no

1999-12-10 Publication of NO995016L publication Critical patent/NO995016L/no

2009-07-06 Publication of NO327455B1 publication Critical patent/NO327455B1/no

Links

PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical class C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 title abstract description 14
239000000825 pharmaceutical preparation Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 20
239000000203 mixture Substances 0.000 claims description 7
206010028980 Neoplasm Diseases 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
238000011321 prophylaxis Methods 0.000 claims description 3
230000001225 therapeutic effect Effects 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 2
239000000284 extract Substances 0.000 abstract description 6
230000003389 potentiating effect Effects 0.000 abstract description 3
150000001204 N-oxides Chemical class 0.000 abstract description 2
230000003013 cytotoxicity Effects 0.000 abstract description 2
231100000135 cytotoxicity Toxicity 0.000 abstract description 2
239000012038 nucleophile Substances 0.000 abstract 1
238000013467 fragmentation Methods 0.000 description 8
238000006062 fragmentation reaction Methods 0.000 description 8
238000002000 high resolution fast-atom bombardment mass spectrometry Methods 0.000 description 8
238000004885 tandem mass spectrometry Methods 0.000 description 8
241000798369 Ecteinascidia turbinata Species 0.000 description 6
238000005481 NMR spectroscopy Methods 0.000 description 6
238000000034 method Methods 0.000 description 5
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
230000003595 spectral effect Effects 0.000 description 3
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
241001529936 Murinae Species 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000001382 Experimental Melanoma Diseases 0.000 description 1
208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000016113 North Carolina macular dystrophy Diseases 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
231100000682 maximum tolerated dose Toxicity 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000005556 structure-activity relationship Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000002689 xenotransplantation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/58—1,2-Diazines; Hydrogenated 1,2-diazines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pest Control & Pesticides (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Agronomy & Crop Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Plant Pathology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dentistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Environmental Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Epoxy Compounds (AREA)

NO19995016A 1997-04-15 1999-10-14 Ecteinascidin forbindelser, anvendelser derav samt farmasoytiske preparat NO327455B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4359697P	1997-04-15	1997-04-15
PCT/US1998/007340 WO1998046080A1 (en)	1997-04-15	1998-04-14	Nucleophile substituted ecteinascidins and n-oxide ecteinascidins

Publications (3)

Publication Number	Publication Date
NO995016D0 NO995016D0 (no)	1999-10-14
NO995016L NO995016L (no)	1999-12-10
NO327455B1 true NO327455B1 (no)	2009-07-06

Family

ID=21927969

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19995016A NO327455B1 (no)	1997-04-15	1999-10-14	Ecteinascidin forbindelser, anvendelser derav samt farmasoytiske preparat

Country Status (20)

Country	Link
US (1)	US5985876A (pl)
EP (2)	EP1668985B1 (pl)
JP (1)	JP4382164B2 (pl)
KR (1)	KR100513668B1 (pl)
CN (1)	CN100343235C (pl)
AT (1)	ATE420092T1 (pl)
AU (1)	AU747303B2 (pl)
BR (1)	BR9808588A (pl)
CA (1)	CA2286796C (pl)
CY (1)	CY1108958T1 (pl)
CZ (1)	CZ298842B6 (pl)
DE (1)	DE69840458D1 (pl)
DK (1)	DK1668985T3 (pl)
ES (1)	ES2321019T3 (pl)
HU (1)	HUP0103590A3 (pl)
IL (1)	IL132403A (pl)
NO (1)	NO327455B1 (pl)
PL (2)	PL338508A1 (pl)
PT (1)	PT1668985E (pl)
WO (1)	WO1998046080A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040059112A1 (en) *	1994-02-18	2004-03-25	Rinehart Kenneth L.	Ecteinascidins
KR100643092B1 (ko) *	1998-05-11	2006-11-10	파르마 마르, 에스.에이.	엑테인아시딘 743의 대사산물
MY164077A (en) *	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
AR035842A1 (es)	1999-05-14	2004-07-21	Pharma Mar Sa	Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US7919493B2 (en) *	2000-04-12	2011-04-05	Pharma Mar, S.A.	Anititumoral ecteinascidin derivatives
JP5219323B2 (ja) *	2000-04-12	2013-06-26	ファルマ・マール・ソシエダード・アノニマ	抗腫瘍性エクチナサイジン誘導体
MXPA02011319A (es)	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) *	2000-05-15	2008-09-02	Pharma Mar, S.A.	Synthetic process for the manufacture of an ecteinaschidin compound
EA005564B1 (ru) *	2000-11-06	2005-04-28	Фарма Мар, С.А.	Эффективные противоопухолевые лекарственные средства
GB0117402D0 (en) *	2001-07-17	2001-09-05	Pharma Mar Sa	New antitumoral derivatives of et-743
GB0119243D0 (en) *	2001-08-07	2001-10-03	Pharma Mar Sa	Antitumoral analogs of ET-743
GB0202544D0 (en) *	2002-02-04	2002-03-20	Pharma Mar Sa	The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) *	2003-05-29	2003-07-02	Pharma Mar Sau	Treatment
GB0324201D0 (en) *	2003-10-15	2003-11-19	Pharma Mar Sau	Improved antitumoral combinations
SI1689404T1 (sl) *	2003-11-13	2009-02-28	Pharma Mar Sau	Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
GB0326486D0 (en) *	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
CN1897949A (zh) *	2003-11-14	2007-01-17	马尔药品公司	包含使用et－743和紫杉醇来治疗癌症的联合疗法
AU2005261860A1 (en) *	2004-07-09	2006-01-19	Pharma Mar, S.A.	Use of ecteinascidin in the treatment of cancer in patients with low level of BRCA1
AU2005288696A1 (en) *	2004-09-28	2006-04-06	Pharma Mar S.A., Sociedad Unipersonal	Ecteinascidin compounds as anti -inflammatory agents
RU2359700C2 (ru) *	2004-10-26	2009-06-27	Фарма Мар С.А., Сосьедад Униперсональ	Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
KR101188691B1 (ko)	2004-10-29	2012-10-09	파르마 마르 에스.에이.	엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en)	2005-10-31	2005-12-07	Pharma Mar Sa	Formulations
CA2703026A1 (en) *	2007-10-19	2009-04-23	Rafael Rosell Costa	Prognostic molecular markers for et-743 treatment
DK2786753T3 (en)	2010-11-12	2019-04-15	Pharma Mar Sa	Combination therapy with an antitumor antibiotic
US11332480B2 (en)	2017-04-27	2022-05-17	Pharma Mar, S.A.	Antitumoral compounds
WO2021098992A1 (en)	2019-11-21	2021-05-27	Pharma Mar, S.A.	Methods of treating small cell lung cancer with lurbinectedin formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4273773A (en) *	1979-09-24	1981-06-16	American Home Products Corporation	Antihypertensive tricyclic isoindole derivatives
US5089273A (en) *	1986-06-09	1992-02-18	Board Of Trustees Of The University Of Illinois	Ecteinascidins 729, 743, 745, 759A, 759B and 770
DK0574857T3 (da) *	1992-06-19	1998-05-04	Hoechst Ag	Polycycliske 31668P- og 31668U-forbindelser, fremgangsmåder til deres fremstilling samt deres anvendelse som antibiotiske eller antitumorale lægemidler
US5426108A (en) *	1993-11-10	1995-06-20	American Cyanamid Company	Antibiotic 31F508 ALPHA1, ALPHA2, BETA1 and BETA2
CZ301083B6 (cs) *	1998-04-06	2009-11-04	The Board Of Trustees Of The University Of Illinois	Ekteinascidinová sloucenina, farmaceutický prostredek ji obsahující a její použití

1998
- 1998-04-10 US US09/058,499 patent/US5985876A/en not_active Expired - Fee Related
- 1998-04-14 DK DK06004129T patent/DK1668985T3/da active
- 1998-04-14 AT AT06004129T patent/ATE420092T1/de not_active IP Right Cessation
- 1998-04-14 CZ CZ0367999A patent/CZ298842B6/cs not_active IP Right Cessation
- 1998-04-14 PL PL98338508A patent/PL338508A1/xx not_active Application Discontinuation
- 1998-04-14 KR KR10-1999-7009489A patent/KR100513668B1/ko not_active Expired - Fee Related
- 1998-04-14 EP EP06004129A patent/EP1668985B1/en not_active Expired - Lifetime
- 1998-04-14 WO PCT/US1998/007340 patent/WO1998046080A1/en not_active Ceased
- 1998-04-14 IL IL13240398A patent/IL132403A/en not_active IP Right Cessation
- 1998-04-14 AU AU71114/98A patent/AU747303B2/en not_active Ceased
- 1998-04-14 CN CNB988060760A patent/CN100343235C/zh not_active Expired - Fee Related
- 1998-04-14 DE DE69840458T patent/DE69840458D1/de not_active Expired - Lifetime
- 1998-04-14 EP EP98918132A patent/EP0975218A4/en not_active Ceased
- 1998-04-14 CA CA002286796A patent/CA2286796C/en not_active Expired - Fee Related
- 1998-04-14 JP JP54414098A patent/JP4382164B2/ja not_active Expired - Lifetime
- 1998-04-14 ES ES06004129T patent/ES2321019T3/es not_active Expired - Lifetime
- 1998-04-14 PT PT06004129T patent/PT1668985E/pt unknown
- 1998-04-14 PL PL378729A patent/PL197708B1/pl not_active IP Right Cessation
- 1998-04-14 BR BR9808588-3A patent/BR9808588A/pt not_active IP Right Cessation
- 1998-04-14 HU HU0103590A patent/HUP0103590A3/hu unknown
1999
- 1999-10-14 NO NO19995016A patent/NO327455B1/no not_active IP Right Cessation
2009
- 2009-04-06 CY CY20091100396T patent/CY1108958T1/el unknown

Also Published As

Publication number	Publication date
ATE420092T1 (de)	2009-01-15
EP1668985A3 (en)	2006-11-22
CN100343235C (zh)	2007-10-17
ES2321019T3 (es)	2009-06-01
KR20010006402A (ko)	2001-01-26
PL197708B1 (pl)	2008-04-30
DK1668985T3 (da)	2009-05-04
EP1668985B1 (en)	2009-01-07
IL132403A (en)	2004-09-27
DE69840458D1 (de)	2009-02-26
CA2286796C (en)	2008-08-05
AU7111498A (en)	1998-11-11
CZ367999A3 (cs)	2000-07-12
PL338508A1 (en)	2000-11-06
NO995016D0 (no)	1999-10-14
IL132403A0 (en)	2001-03-19
NO995016L (no)	1999-12-10
CA2286796A1 (en)	1998-10-22
EP0975218A4 (en)	2001-08-08
HUP0103590A2 (hu)	2002-01-28
CZ298842B6 (cs)	2008-02-20
PT1668985E (pt)	2009-04-09
WO1998046080A1 (en)	1998-10-22
KR100513668B1 (ko)	2005-09-08
HUP0103590A3 (en)	2002-07-29
BR9808588A (pt)	2000-05-23
CN1261254A (zh)	2000-07-26
JP4382164B2 (ja)	2009-12-09
JP2001523228A (ja)	2001-11-20
AU747303B2 (en)	2002-05-16
CY1108958T1 (el)	2012-05-23
EP0975218A1 (en)	2000-02-02
US5985876A (en)	1999-11-16
EP1668985A2 (en)	2006-06-14

Legal Events

Date	Code	Title	Description
2011-11-28	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
CA2286796C (en)	2008-08-05	Nucleophile substituted ecteinascidins and n-oxide ecteinascidins
Feldman	2005	Recent progress in ellagitannin chemistry
CA3154073A1 (en)	2021-06-24	Isoindolinone and indazole compounds for the degradation of egfr
RU2225864C2 (ru)	2004-03-20	Метаболиты эктейнасцидина-743, фармацевтическая композиция на их основе и способы лечения
JP7618567B2 (ja)	2025-01-21	架橋型光学活性２級アミン誘導体
JP2021535909A (ja)	2021-12-23	高活性ｓｔｉｎｇタンパク質アゴニスト化合物
JP2019521982A (ja)	2019-08-08	ヘテロアリールエストロゲン受容体モジュレーター及びその使用
JP5149001B2 (ja)	2013-02-20	癌の処置におけるマイグラスタチンアナログ
US9962383B2 (en)	2018-05-08	Compounds, compositions and methods of agelastatin alkaloids
JPH06234635A (ja)	1994-08-23	インターロイキン１ベータを阻害するためのレフルノミドの使用
EP3187183B1 (en)	2020-04-08	Fk506 derivative maintaining nerve regeneration activity without immunosuppressive activity, and use thereof
WO2008052352A1 (en)	2008-05-08	Substituted quinone indoleamine 2,3-dioxygenase (ido) inhibitors and syntheses and uses therefor
EP0566666B1 (en)	1999-08-11	Novel glucohydrolase inhibitors useful as antidiabetic antivital and antimetastatic agents
WO2003069303A2 (en)	2003-08-21	Antimalarial and antiproliferative pharmacophore models, novel tryptanthrin compounds having increased solubility, and methods of making and using thereof
CN117003737A (zh)	2023-11-07	取代的咪唑苯基甲酮类化合物及其衍生物和药物组合物
MXPA99009503A (en)	2000-08-01	Nucleophile substituted ecteinascidins and n-oxide ecteinascidins
RU2221800C2 (ru)	2004-01-20	Алкалоиды, способ их получения, способы лечения, фармацевтический состав
EP4722209A1 (en)	2026-04-08	Protac compound targeting estrogen receptor, preparation method therefor, and use thereof
WO2005011673A1 (en)	2005-02-10	Use of antitumoral compounds
JP2005314236A (ja)	2005-11-10	新規クアシノイド系化合物及びそれらの用途
Chadda	2017	Carbohydrates as precursors to macrocyclic and iminosugar frameworks
CN120965718A (zh)	2025-11-18	取代三环类抑制剂及其制备方法和应用
US20030092729A1 (en)	2003-05-15	Tropane alkaloid multidrug resistance inhibitors from Erythroxylum pervillei and use of the same
CN120682256A (zh)	2025-09-23	环基取代芳杂环类抑制剂及其制备方法和应用